SCHEMBL5480073

SCHEMBL5480073

CS(=O)(=O)Nc1ccc(C2(c3ccc(NS(C)(=O)=O)cc3)C(=O)Nc3c2ccc2ccccc32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.44
KEAP1 Q14145 2/20 0.41
KDM1A O60341 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CASP1 P29466 1/20 0.40
CASP7 P55210 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
CNR1 P21554 1/20 0.39
HTT P42858 1/20 0.39
GPR35 Q9HC97 1/20 0.39
GPR55 Q9Y2T6 1/20 0.39
KCNH2 Q12809 1/20 0.38
PGR P06401 1/20 0.38
NR3C2 P08235 2/20 0.37
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
CSNK2A1 P68400 1/20 0.36
AURKA O14965 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5482648 0.81 SMN1; SMN2 (0.62) KDM1ASMN1; SMN2CNR1HTTGPR35
SCHEMBL5475329 0.79 CNR1 (0.57) CYP1A2CNR1HTTGPR35GPR55
SCHEMBL5478213 0.79 CNR1 (0.40) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5485875 0.78 CNR1 (0.41) CYP1A2CYP2D6CYP2C9SMN1; SMN2CNR1
SCHEMBL5485549 0.76 KIF11 (0.40) KEAP1SMN1; SMN2CNR1HTTGPR35
SCHEMBL5482098 0.75 HTT (0.39) METKEAP1SMN1; SMN2CNR1HTT
SCHEMBL5477973 0.74 MAPT (0.62) SMN1; SMN2CNR1HTTGPR35GPR55
SCHEMBL5478650 0.73 KIF11 (0.38) KEAP1SMN1; SMN2CNR1HTTGPR35
SCHEMBL5482451 0.69 SMN1; SMN2 (0.38) KEAP1CYP2C9SMN1; SMN2HTTPGR
SCHEMBL5482310 0.69 SMN1; SMN2 (0.38) KEAP1CYP2C9SMN1; SMN2HTTPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 MET 704/4885KEAP1 1542/4885KDM1A 757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.